We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Emerging Technologies Boost European IVD Markets

By Labmedica staff writers
Posted on 07 Nov 2006
The emergence and widening adoption of new technologies are boosting the revenue prospects of European in vitro diagnostics (IVD) markets.

Frost & Sullivan (Palo Alto, CA, USA), a global growth-consulting company, reported that the European IVD markets earned revenues of U.S.$6.60 billion in 2005 and estimates they will reach U.S.$9.95 billion in 2012.

"The adoption of new technologies, such as molecular and point-of-care testing, combined with the increasing trend towards laboratory automation will drive growth in the European IVD markets,” noted Frost & Sullivan research associate A.K. More...
Arun. "An emphasis on providing high quality healthcare and ensuring timely diagnosis is driving the adoption of these clinical tests and automated solutions while promoting market growth.”

Emerging markets such as molecular testing and near testing are supporting established segments such as clinical chemistry and hematology, thereby spurring market expansion. Moreover, labor shortages are pressurizing clinical laboratories to adopt high throughput and modular solutions, reinforcing growth in the market.

However, challenges still exist in the industry. Demographic changes combined with new diseases are compelling IVD manufacturers to increase their R&D investments. At the same time, competition has led to price erosion, squeezing revenue returns for market participants. In addition, the growing popularity of emerging segments could overshadow mature segments in the market.

A focused strategy will be vital for IVD manufacturers to ensure sufficient returns on investment. In the present market scenario, approaches centering on competitive pricing, new and innovative products, a broad product portfolio, and novel technologies will allow companies to gain a competitive edge.



Related Links:
Frost & Sullivan

Gold Member
Automatic Hematology Analyzer
DH-800 Series
Portable Electronic Pipette
Mini 96
Gel Cards
DG Gel Cards
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Size assessment of patient-derived material from various tauopathies (Aragonès Pedrola J. et al., PNAS (2025); DOI: 10.1073/pnas.2502847122)

First Direct Measurement of Dementia-Linked Proteins to Enable Early Alzheimer’s Detection

The disease process in Alzheimer’s begins long before memory loss or cognitive decline becomes apparent. During this silent phase, misfolded proteins gradually form amyloid fibrils, which accumulate in... Read more

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Microbiology

view channel
Image: EBP and EBP plus have received FDA 510(k) clearance and CE-IVDR Certification for use on the BD COR system (Photo courtesy of BD)

High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample

Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.